M
Martina Schmidt
Researcher at University of Mainz
Publications - 426
Citations - 16809
Martina Schmidt is an academic researcher from University of Mainz. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 63, co-authored 394 publications receiving 15119 citations. Previous affiliations of Martina Schmidt include Nara Institute of Science and Technology & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Controlled-release experiment to investigate uncertainties in UAV-based emission quantification for methane point sources
Randulph P. Morales,Jonas Ravelid,Katarina Vinkovic,Piotr Korbeń,Béla Tuzson,Lukas Emmenegger,Huilin rer. nat. Chen,Martina Schmidt,Sebastian Humbel,Dominik Brunner +9 more
TL;DR: In this paper , the authors present the results of an extensive controlled-release experiment in Dübendorf, Switzerland, which was conducted to develop an optimal quantification method and to determine the related uncertainties under various environmental and sampling conditions.
Journal ArticleDOI
Young age at school entry and attention-deficit hyperactivity disorder-related symptoms during primary school: results of a prospective cohort study conducted at German Rudolf Steiner Schools.
TL;DR: Previous evidence of the association between young ASE and teacher-reported ADHD symptoms in primary school was confirmed, using a prospective study design and comprehensive adjustment for confounding and baseline symptoms.
Journal ArticleDOI
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.
A. Mavratzas,S. Baek,Bernd Gerber,Martina Schmidt,V. Moebus,F. Foerster,E-M. Grischke,Peter A. Fasching,Dirk Strumberg,Erich-Franz Solomayer,P. Klare,C. Windemuth-Kieselbach,S. Hartmann,Andreas Schneeweiss,Frederik Marmé +14 more
TL;DR: Addition of sorafenib to taxane-based first-line chemotherapy in patients with metastatic breast cancer failed to improve PFS and resulted in increased toxicity.
Journal ArticleDOI
ASCO-recommended prognostic factors uPA/PAI-1 in node-negative (N0) breast cancer patients (pts) compared to clinicopathological risk assessment within the NNBC 3-Europe trial
C. Thomssen,Martina Vetter,Martina Schmidt,Corinne Veyret,Christoph Meisner,G. von Minckwitz,P M Martin,Fred C.G.J. Sweep,Daniela Paepke,Nadia Harbeck +9 more
TL;DR: Routine uPA/PAI-1 determination is reliable and feasible even in core needle specimens, and adjuvant chemotherapy may be avoided in about 39% of N0 breast cancer pts.
Journal Article
New prognostic and predictive factors in breast cancer.
TL;DR: Prognostic factors, ER, HER-2 and potentially newer prognostic factors like epithelial cell adhesion molecule (Ep-CAM) bridge the gap from prognosis to prediction and serve as therapeutic targets, leading to a more personalized treatment recommendation.